Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Transl Immunology
Huvudupphovsmän: Kammüller, Michael, Tsai, Tsen-Fang, Griffiths, Christopher EM, Kapoor, Nidhi, Kolattukudy, Pappachan E, Brees, Dominique, Chibout, Salah-Dine, Safi Jr, Jorge, Fox, Todd
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2017
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5579471/
https://ncbi.nlm.nih.gov/pubmed/28868144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cti.2017.34
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk